Solasia Pharma KK AI Stock Analysis
Want to see JP:4597 full AI Analyst Report?
Solasia Pharma KK (4597) AI Stock Analysis
Solasia Pharma KK
(TSE/TYO:4597)
Solasia Pharma scores poorly, driven primarily by weak financial performance: persistent operating losses, a TTM net loss of ¥830M on just ¥684M of revenue, and a cash burn of ¥1,127M that exceeds the loss itself. With equity of ¥1,345M being steadily consumed, further capital raises and dilution appear likely, even though the near-debt-free balance sheet limits solvency risk. Encouraging signs include ~76% TTM revenue growth, a return to a ~44% gross margin, and losses roughly a third of 2022 levels, but the gap to breakeven remains wide. Technicals reinforce caution, with the price below all key moving averages and negative MACD momentum, while a negative P/E and no dividend leave no valuation cushion. Note: the computed weighted average falls below the platform floor, so the score is set at the minimum of 37.
Solasia Pharma KK (4597) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.55B
- Dividend Yield
- ―
- Average Volume (3M)
- 77.14M
- Price to Earnings (P/E)
- -7.9
- Beta (1Y)
- 1.33
- Revenue Growth
- 109.82%
- EPS Growth
- 61.98%
- Country
- Japan
- Employees
- 22
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Solasia Pharma KK Business Overview & Revenue Model
Company Description
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil or...
How the Company Makes Money
Solasia Pharma generally makes money through (1) licensing and collaboration agreements for its drug candidates and/or marketed products, under which it may receive upfront payments, development and regulatory milestone payments, and sales-based roya...
Solasia Pharma KK Financial Statement Overview
Summary
Solasia remains a pre-profitability specialty pharma with deep structural weaknesses. The income statement (score 22) shows small, erratic revenue (¥684M TTM, +76%) and a TTM net loss of ¥830M, equal to roughly 120% of sales, despite a recovery in gross margin to about 44%. Cash flow (score 16) is the weakest link: operating cash flow has been negative in every period, with burn widening to ¥1,127M on a TTM basis — more than the net loss — indicating working capital drag and dependence on external funding. The balance sheet (score 45) is the relative bright spot, with minimal debt (¥69M vs. ¥1,345M equity, D/E ~0.05) and equity funding ~86% of assets, but equity is eroding from continuous losses (ROE ~-54%), implying likely further capital raises and shareholder dilution within roughly a year at the current burn rate.
Income Statement
22NegativeBalance Sheet
45NeutralCash Flow
16Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 684.00M | 429.00M | 316.00M | 617.00M | 1.09B | 559.00M |
| Gross Profit | 298.00M | 171.00M | -10.00M | -163.00M | 128.00M | -121.00M |
| EBITDA | -787.00M | -822.00M | -796.00M | -639.00M | -1.20B | -1.92B |
| Net Income | -830.00M | -876.00M | -1.94B | -1.11B | -2.55B | -2.48B |
Balance Sheet | ||||||
| Total Assets | 1.56B | 2.15B | 1.36B | 2.55B | 3.56B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 1.02B | 1.39B | 886.00M | 728.00M | 803.00M | 714.00M |
| Total Debt | 69.00M | 159.00M | 25.00M | 60.00M | 37.00M | 84.00M |
| Total Liabilities | 213.00M | 392.00M | 203.00M | 673.00M | 899.00M | 1.17B |
| Stockholders Equity | 1.34B | 1.75B | 1.16B | 1.88B | 2.66B | 2.59B |
Cash Flow | ||||||
| Free Cash Flow | -1.13B | -847.00M | -1.03B | -359.00M | -2.07B | -2.48B |
| Operating Cash Flow | -1.13B | -847.00M | -1.03B | -359.00M | -2.07B | -2.47B |
| Investing Cash Flow | -36.00M | -81.00M | 0 | 2.00M | -418.00M | -164.00M |
| Financing Cash Flow | 319.00M | 1.43B | 1.18B | 275.00M | 2.57B | 361.00M |
Solasia Pharma KK Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4597, the sentiment is Negative. The current price of 24.00 is below the 20-day moving average (MA) of 25.45, below the 50-day MA of 27.84, and below the 200-day MA of 29.16, indicating a bearish trend. The MACD of -1.25 indicates Positive momentum. The RSI at 42.10 is Neutral, neither overbought nor oversold. The STOCH value of 36.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4597.
Solasia Pharma KK Peers Comparison
Overall Rating
JP:457469Neutral
JP:458248Neutral
JP:453946Neutral
JP:488342Neutral
JP:489242Neutral
JP:459733Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | JPY 12.82B | 30.32 | ― | 1.29% | 13.72% | -50.46% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | JPY 7.16B | -0.82 | ― | ― | -30.58% | 6.93% | |
| 46Neutral | JPY 5.57B | -11.41 | ― | 3.24% | 0.31% | -194.72% | |
| 42Neutral | JPY 3.73B | -1.41 | ― | ― | ― | 25.34% | |
| 42Neutral | JPY 5.08B | -6.53 | ― | ― | 214.65% | 22.18% | |
| 33Underperform | JPY 6.55B | -7.89 | -53.06% | ― | 109.82% | 61.98% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4597 | Solasia Pharma KK | 24.00 | -7.00 | -22.58% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1543.00 | 68.97 | 4.68% | |
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 256.00 | -35.00 | -12.03% | |
| JP:4582 | Symbio Pharmaceuticals Limited | 71.00 | -33.00 | -31.73% | |
| JP:4883 | Modalis Therapeutics Corporation | 31.00 | -36.00 | -53.73% | |
| JP:4892 | Cyfuse Biomedical K.K. | 515.00 | -69.00 | -11.82% |
Solasia Pharma KK Corporate Events
Solasia Updates Pipeline and Commercialization Activities
Solasia Pharma reported its third-quarter fiscal 2026 pipeline and product-status update. In China, partner MAAB began selling Sancuso in April 2026, completed the transition of sales operations from Lee’s Pharmaceutical, and received product shipmen...
Solasia Pharma Reports Higher Sales, Narrower Nine-Month Operating Loss
Solasia Pharma K.K. is listed on the Tokyo Stock Exchange’s Growth market under securities code 4597. It reported consolidated results for the nine months ended Sept. 30, 2026.Sales rose 277.3% year on year to ¥346 million, while operating loss narro...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
